Higher Genetic Barrier Revealed in HCV GT-1b/2/4/6 Subjects than GT-1a Patients – A Proof of Concept Trial of TG-2349 (Furaprevir)
Yeh, C.-T, Hsu, S.-J, Hu, T.-H, Liu, C.-J, Tsai, C.-E, Chen, C.-M, Chang, L.-W, Lin, C.-C, King, C.-H.R, Hsu, M.-C
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
TG-2349, a Potent Protease Inhibitor, Plus Pegifn/RBV Provides Excellent Virological Responses for Harder-To-Treat Subpopulations of HCV-1B Non-Cirrhotic Patients
Yu, M.-L, Hsu, S.-J, Yeh, C.-T, Hung, C.-H, Chen, M.-Y, Chen, P.-J, Huang, Y.- H, Cheng, P.-N, Chen, C.-M, Chang, L.-W, Lin, C.-C, Sheen, F, King, C.-H.R, Kuo, E, Hsu, M.-C
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
SAT-125 - Higher Genetic Barrier Revealed in HCV GT-1b/2/4/6 Subjects than GT-1a Patients – A Proof of Concept Trial of TG-2349 (Furaprevir)
Yeh, C.-T., Hsu, S.-J., Hu, T.-H., Liu, C.-J., Tsai, C.-E., Chen, C.-M., Chang, L.-W., Lin, C.-C., King, C.-H.R., Hsu, M.-C.
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
SAT-219 - TG-2349, a Potent Protease Inhibitor, Plus Pegifn/RBV Provides Excellent Virological Responses for Harder-To-Treat Subpopulations of HCV-1B Non-Cirrhotic Patients
Yu, M.-L., Hsu, S.-J., Yeh, C.-T., Hung, C.-H., Chen, M.-Y., Chen, P.-J., Huang, Y.- H., Cheng, P.-N., Chen, C.-M., Chang, L.-W., Lin, C.-C., Sheen, F., King, C.-H.R., Kuo, E., Hsu, M.-C.
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
Castanospermine-glucosides are potent, selective, long-acting sucrase inhibitors
Robinson, K M, Rhinehart, B L, Begovic, M E, King, C H, Liu, P S
Published in The Journal of pharmacology and experimental therapeutics (01.10.1989)
Get full text
Published in The Journal of pharmacology and experimental therapeutics (01.10.1989)
Journal Article